Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-CD19 CAR-T cells in Refractory Systemic Lupus Erythematosus
NCT06222853Phase 1Active, not recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of puzolcabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Safety of CAR-T cells at 3 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
puzolcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06222853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222853.